Gontivimab
Modify Date: 2024-04-06 09:07:04
Gontivimab structure
|
Common Name | Gontivimab | ||
|---|---|---|---|---|
| CAS Number | 1257358-38-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GontivimabGontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung[1]. |
| Name | Gontivimab |
|---|
| Description | Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung[1]. |
|---|---|
| Related Catalog | |
| Target |
KD: 0.113 nM (RSV prefusion F protein)[1] |
| In Vitro | Gontivimab (0-100000 nM) 显示出抗病毒活性，对 RSV-A、RSV-B 18537 菌株的 IC50 分别为 0.1、0.4 nM[1]。 Gontivimab 与 F 蛋白的抗原位点 II 结合[1]。 |
| In Vivo | Gontivimab (1-68 mg/kg；鼻内给药或雾化) 降低大鼠鼻腔和肺部的 RSV 负荷[1]。 Animal Model: Rats (RSV Tracy)[1] Dosage: 1-68 mg/kg Administration: Intranasal administration or nebulization; once (day 2 or day 3) or twice (day 2 and day 3) Result: Resulted in significant viral load reductions in the lungs ranging. |
| References |
| No Any Chemical & Physical Properties |